4Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM- 2004 study [J]. Haematologica,2006,91 (8) : 1068-1075.
5Ruping M J, Vehresehild J J, Comely O A. Patients at high risk of invasive fungal infections: when and how to treat [J]. Drugs,2008, 68(14) : 1941-1962.
6Bohme A, Ruhnke M, Buchheidt D, et al. Treatment of invasive fungal infections in cancer patients-recommendations of the Infectious Diseases Working Party (AGIHO)of the German Society of Hematology and Oncology (DGHO) [ J ]. Ann Hematol, 2009,88 ( 1 ) : 97-110.
7Groll A H, Gea-Banacloche J C, Glasmacher A, et al. Clinical pharmacology of antifungal compounds [J]. Infect Dis Clin North Am,2003,17(2) : 159-191.
8Auletta J J, Lazarus H M. Immune restoration following hematopoietie stem cell transplantation:an evolving target [J]. Bone Marrow Transplant, 2005,35 (9) : 835-857.
9Greer N D. Voriconazole: the newest triazole antifungal agent [J]. Pro(Bayl Univ Med Cent) ,2003,16(2) :241-248.
10Hof H.Developments in the epidemiology of invasive fun infectionsimplications for the empiric and targeted antifungal therapy[J].Mycoses,2008,51:1.